sur Jaguar Health, Inc. (NASDAQ:JAGX)
Jaguar Health Reports Positive Trial Results for Canalevia-CA1
On April 29, 2026, Jaguar Health, Inc. (NASDAQ:JAGX) revealed promising results from its trial on crofelemer, marketed as Canalevia-CA1, intended for treating chemotherapy-induced diarrhea (CID) in dogs. The study highlighted that dogs treated with Canalevia-CA1 showed a return to normal stool consistency after three days, according to the company.
An owner survey showed that 83% of respondents found the treatment effective, while 40% reported complete resolution of their pet's CID. These findings significantly outperform the mere 12.5% improvement observed in those untreated. Jaguar Health plans to seek full FDA approval based on these outcomes.
The effectiveness trial also aligns with Jaguar's broader strategy to use crofelemer for various diarrhea-related conditions in companion animals. The company emphasizes the potential of this anti-secretory treatment.
Safety information indicates Canalevia-CA1 is for canine use only, with caution advised due to potential adverse reactions.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Jaguar Health, Inc.